[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.202.12. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 419
Citations 0
Comment & Response
August 9, 2016

Cost of Antihyperglycemic Medications in the United States

Author Affiliations
  • 1Eli Lilly, Indianapolis, Indiana
JAMA. 2016;316(6):665. doi:10.1001/jama.2016.8587

To the Editor Ms Hua and colleagues1 compared 2002-2013 trends in diabetes drug expenditures, particularly insulins, using the Medical Expenditure Panel Survey (MEPS). We note important limitations to their analysis and conclusions. The findings revealed recent dynamic changes in insurance benefit design as higher cost exposure shifts to consumers, but the authors overstated price and did not consider significant changes in diabetes care and the US insurance landscape during the study period.

First Page Preview View Large
First page PDF preview
First page PDF preview
×